Does Humana Cover Wegovy?

Humana Commercial Plan Coverage for Wegovy

Most Humana employer-sponsored and individual marketplace plans can cover Wegovy, but the drug typically sits on a high specialty tier with mandatory prior authorization. Your Summary of Benefits and Coverage (SBC) document is the only definitive source for your plan's formulary status.

Humana's commercial formulary committees evaluate anti-obesity medications against the FDA-approved labeling for semaglutide 2.4 mg, which limits the indication to adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia [1]. Plans that do include Wegovy generally place it on Tier 5 or Tier 6 (non-preferred specialty), meaning your out-of-pocket cost after prior authorization approval may still range from $150 to $500 per month depending on your plan's coinsurance structure.

A 2024 KFF employer benefits survey found that roughly 40% of large employer plans covered at least one GLP-1 receptor agonist for weight management [2]. That number is growing, but coverage varies widely. Some Humana group plans carved out anti-obesity medications entirely to control pharmacy spend. If your plan document lists "anti-obesity agents" under the exclusions section, Wegovy will not be covered regardless of medical necessity. Check your SBC or call the number on the back of your Humana ID card before assuming coverage.

Humana Medicare Advantage and Wegovy

Medicare Part D has historically excluded coverage for drugs used for anorexia, weight loss, or weight gain. That exclusion applies to most Humana Medicare Advantage prescription drug plans (MA-PDs).

The Treat and Reduce Obesity Act has been introduced in multiple congressional sessions to remove this exclusion, but as of May 2026, CMS rules still permit Part D plans to exclude anti-obesity medications [3]. One exception exists: if you have a separate FDA-approved indication for semaglutide (such as cardiovascular risk reduction, based on the SELECT trial results), your prescriber may be able to request coverage under a different diagnosis code [4]. This is not a guaranteed workaround. It depends on how Humana's pharmacy benefit manager adjudicates the claim.

Some Humana MA plans began offering limited supplemental benefits for weight management programs in plan year 2025. These benefits typically cover counseling or meal-replacement programs rather than prescription drugs. Check your Annual Notice of Changes (ANOC) document for specifics.

Prior Authorization Criteria for Wegovy on Humana

Humana requires prior authorization for Wegovy on all plans where the drug appears on formulary. The criteria are drawn from the FDA label and from evidence established in trials like STEP-1 [5].

To meet typical PA requirements, your prescriber will need to document:

1. A BMI of 30 or greater (obesity), or a BMI of 27 or greater (overweight) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease.
2. Failure of, or contraindication to, a structured diet-and-exercise program lasting at least 6 months. Some plans accept 3 months.
3. The prescriber is a physician, nurse practitioner, or physician assistant. Some plans require specialist involvement (endocrinologist or obesity medicine physician).
4. The patient does not have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, consistent with the boxed warning on the Wegovy label [1].

PA approvals are typically granted for 6 to 12 months. Reauthorization requires documentation of at least 5% body weight loss from baseline. In STEP-1 (N=1,961), participants receiving semaglutide 2.4 mg achieved a mean weight loss of 14.9% at 68 weeks compared with 2.4% in the placebo group [5]. That level of response exceeds most reauthorization thresholds comfortably.

Dr. Robert Kushner, professor of medicine at Northwestern University Feinberg School of Medicine and a principal investigator in the STEP trials, has stated: "The magnitude of weight loss with semaglutide 2.4 mg is unlike anything we have seen with prior pharmacotherapy for obesity" [5]. Meeting the 5% reauthorization bar should not be the obstacle for most responders. Getting through the initial approval is the harder step.

Does Humana Require Step Therapy Before Wegovy?

Some Humana plans impose step therapy, meaning you must try and fail a lower-cost or older anti-obesity medication before the plan will authorize Wegovy. The most common step-therapy agents include phentermine, phentermine-topiramate (Qsymia), and naltrexone-bupropion (Contrave).

Step therapy is not universal across all Humana plans. It varies by plan design. The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity recommends GLP-1 receptor agonists as first-line pharmacotherapy for patients with a BMI of 30 or greater when lifestyle modification alone has been insufficient [6]. If your plan requires step therapy and your prescriber believes it is not clinically appropriate (for example, phentermine is contraindicated in patients with uncontrolled hypertension or cardiovascular disease), your provider can request a step-therapy exception.

A step-therapy exception request typically needs a letter from the prescriber explaining why the required step agent is medically inappropriate. Response times vary: Humana must respond to a standard exception request within 72 hours for commercial plans and within 24 hours for expedited requests involving urgent clinical need [7].

How to Appeal a Humana Denial of Wegovy

Denials happen. When Humana denies a prior authorization for Wegovy, you have the right to appeal. The process has two stages for commercial plans and up to five stages for Medicare Advantage.

Commercial plan appeals. You or your prescriber can file an internal appeal within 180 days of the denial. Include updated clinical documentation: lab results, weight history, comorbidity records, and a letter of medical necessity from the prescriber. Humana must issue a decision within 30 calendar days for a standard appeal or 72 hours for an expedited appeal [7]. If the internal appeal fails, you can request an external review by an independent review organization (IRO). The IRO decision is binding on Humana.

Medicare Advantage appeals. The MA appeal process follows CMS rules. After the initial plan-level redetermination (which must be decided within 7 days for standard requests), you can escalate to a reconsideration by an Independent Review Entity (currently MAXIMUS Federal Services). Subsequent levels include an Administrative Law Judge hearing, the Medicare Appeals Council, and federal district court [3]. Given the Part D exclusion for weight-loss drugs, MA appeals for Wegovy face a steep uphill path unless the claim is coded under a covered indication such as cardiovascular risk reduction.

According to CMS data, approximately 75% of Part D coverage determination requests that are initially denied are eventually overturned at some level of appeal [3]. The American Medical Association's 2023 prior authorization physician survey found that 34% of physicians reported that a PA process had led to a serious adverse event for a patient [8]. Document everything.

Manufacturer Savings Card and Other Cost-Reduction Options

Novo Nordisk offers the Wegovy Savings Card for commercially insured patients. Eligible patients may pay as little as $0 for a 28-day supply, with a maximum savings benefit that resets annually. The card cannot be used with government insurance programs, including Medicare, Medicaid, or TRICARE, per federal anti-kickback statute requirements [9].

If you have Humana commercial insurance and your plan covers Wegovy but your out-of-pocket cost is high, combining your plan benefit with the savings card can reduce your monthly expense significantly. Patients without any insurance coverage can explore the Novo Nordisk Patient Assistance Program (PAP), which provides Wegovy at no cost to qualifying individuals with household incomes at or below 400% of the federal poverty level [9].

Other cost-reduction strategies include:

• Asking your prescriber about compounded semaglutide. The FDA has noted that compounded versions are not FDA-approved and carry quality and safety uncertainties [10]. Compounded semaglutide is available through some telehealth platforms at a fraction of the brand cost but is not interchangeable with Wegovy from a regulatory standpoint.
• Checking whether your employer offers a separate obesity-management benefit or health-reimbursement arrangement that could offset costs.
• Using Humana's mail-order specialty pharmacy, which sometimes offers lower copays than retail specialty pharmacies.

What the Clinical Evidence Says About Wegovy

Understanding the clinical data behind Wegovy strengthens both your PA application and any potential appeal. The STEP trial program is the largest evidence base for semaglutide 2.4 mg in chronic weight management.

In STEP-1 (N=1,961), 86.4% of participants receiving semaglutide 2.4 mg achieved at least 5% body weight loss at 68 weeks, compared with 31.5% in the placebo group [5]. The mean weight loss was 14.9% vs. 2.4%. Participants also experienced significant improvements in cardiometabolic risk factors including waist circumference, systolic blood pressure, and C-reactive protein.

The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% compared with placebo in adults with overweight or obesity and established cardiovascular disease, without diabetes [4]. That result led to a supplemental FDA indication for cardiovascular risk reduction in March 2024. This indication is significant for Humana coverage because cardiovascular risk reduction is a distinct clinical endpoint from weight loss, and plans (including some MA-PDs) that exclude weight-loss drugs may cover semaglutide under the cardiovascular indication.

The Endocrine Society guideline gives semaglutide 2.4 mg a strong recommendation (Grade 1, moderate-quality evidence) for adults with BMI ≥30 who have not achieved sufficient weight loss with lifestyle intervention alone [6]. Including this guideline citation in your PA or appeal documentation provides evidence that the prescription aligns with expert consensus.

Tips for Getting Wegovy Covered by Humana

The difference between an approved and denied PA often comes down to documentation quality. Here are specific actions that improve your odds.

Have your prescriber submit the PA with a detailed letter of medical necessity that references the specific Humana PA criteria, not a generic template. Include your exact BMI (calculated from a recent office visit, not self-reported), a list of weight-related comorbidities with ICD-10 codes, and documentation of prior lifestyle intervention. If you have tried and failed other weight-loss medications, include dates, doses, duration, and reason for discontinuation.

Request a peer-to-peer review if the initial PA is denied. In a peer-to-peer, your prescriber speaks directly with a Humana medical director. This conversation often resolves denials that were based on incomplete documentation rather than a true policy exclusion [8].

Keep a copy of every submission, denial letter, and appeal document. Track dates carefully. Missing an appeal deadline forfeits your right to that level of review. A single missed 60-day window on a Medicare appeal cannot be reopened except under limited "good cause" exceptions.

The list price of Wegovy is $1,349 per month [9]. Over a year, that is $16,188 out of pocket without coverage. The time spent on PA paperwork and appeals is a worthwhile investment against that cost.